VCYT
HealthcareVeracyte, Inc. · Biotechnology · $4B
What is Veracyte, Inc.?
Veracyte is a genomic diagnostics company helping physicians make more confident cancer-related decisions — reducing unnecessary surgeries and guiding treatment choices across multiple cancer types. Headquartered in South San Francisco, California, it serves patients and clinicians worldwide.
Veracyte develops and commercializes genomic tests that classify ambiguous or hard-to-diagnose tissue samples. Its tests span thyroid, prostate, breast, lung, and colon cancers, as well as interstitial lung disease. Rather than relying on traditional pathology alone, Veracyte's classifiers use genomic sequencing to give clinicians clearer guidance — helping patients avoid unnecessary procedures and enabling more targeted treatment plans. The company also licenses its technology to partners including Johnson & Johnson and CareDx.
Veracyte was incorporated in 2006 and is headquartered in South San Francisco, California.
- Afirma Genomic Sequencing Classifier — thyroid nodule benign/malignant classification
- Decipher Prostate — biopsy and post-surgery prostate cancer risk assessment
- Prosigna Breast Cancer Assay — recurrence risk profiling for breast cancer patients
- Percepta Genomic Sequencing Classifier — lung cancer detection and diagnosis
- Envisia Genomic Classifier — idiopathic pulmonary fibrosis diagnosis
Is VCYT a Good Stock to Buy?
UQS Score rates VCYT as Good overall, reflecting a balanced profile with notable strengths and areas to watch.
Veracyte's Risk pillar stands out as Strong, suggesting the company carries a relatively controlled risk profile compared with many peers in the diagnostics space. Its Growth pillar also rates Good, consistent with a business expanding its test menu and commercial reach across multiple cancer categories. Valuation similarly rates Good, indicating the market's pricing is not considered excessive relative to the company's fundamentals.
Both the Quality and Moat pillars rate Neutral, pointing to areas where Veracyte has not yet established the same degree of differentiation or financial consistency seen in the sector's top-rated names.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does VCYT pay dividends?
No — Veracyte, Inc. does not currently pay a dividend.
Veracyte does not currently pay a dividend. As a growth-oriented diagnostics company, it reinvests available capital into expanding its genomic test portfolio, broadening clinical evidence, and growing its commercial infrastructure. Investors drawn to VCYT are typically focused on long-term business development rather than near-term income distribution.
When does VCYT report earnings?
Veracyte reports earnings on a quarterly cadence, typical for US-listed equities.
Each quarterly report gives investors a window into test volume trends, revenue mix across cancer categories, and progress on newer product launches. Veracyte's growth trajectory and operating leverage are key focal points for the market each reporting cycle.
For the most recent quarter's results, visit Veracyte's investor relations page directly.
VCYT Price History
-14.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Veracyte, Inc.?
Based on Veracyte, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
VCYT Long-term Outlook
Veracyte's Good Growth pillar suggests the business is on a credible expansion path, driven by increasing clinical adoption of its genomic classifiers and a broadening test menu. Its Strong Risk rating indicates the company is navigating execution and financial risks relatively well for a mid-cap diagnostics name. That said, Neutral Quality and Moat ratings are a reminder that durable competitive advantages and consistent financial returns are still being established. The outlook hinges on continued test volume growth and successful commercialization of pipeline products.
Growth drivers
- Expanding clinical adoption of existing genomic classifiers across thyroid, prostate, and lung cancer
- Pipeline products such as Percepta Genomic Atlas and LymphMark broadening the addressable market
- Technology licensing and collaboration arrangements providing additional revenue streams
Key risks
- Neutral Moat rating signals limited pricing power and potential vulnerability to competing diagnostic platforms
- Reimbursement and coverage decisions by payers can materially affect test volumes and revenue
- Execution risk in scaling newer tests while maintaining commercial momentum in established products
VCYT vs Peers
Veracyte operates in a competitive diagnostics and life sciences landscape alongside companies with distinct business models and therapeutic focuses.
Zai Lab is a biopharmaceutical company focused on oncology and infectious disease therapies, contrasting with Veracyte's purely diagnostics-driven model.
Soleno Therapeutics concentrates on rare disease drug development, representing a different risk and revenue profile compared to Veracyte's commercial test portfolio.
Disc Medicine targets hematologic diseases through novel therapeutics, occupying a different niche within the broader healthcare sector than Veracyte's genomic diagnostics focus.
Frequently Asked Questions
What does Veracyte do?
Veracyte develops genomic diagnostic tests that help physicians classify ambiguous cancer-related tissue samples. Its tests cover thyroid, prostate, breast, lung, and colon cancers, as well as interstitial lung disease. By using genomic sequencing rather than traditional pathology alone, Veracyte helps patients avoid unnecessary surgeries and enables more targeted treatment decisions.
Does VCYT pay dividends?
Veracyte does not pay a dividend. The company reinvests capital into expanding its genomic test portfolio and growing its commercial presence. Investors in VCYT are generally seeking growth rather than income.
When does VCYT report earnings?
Veracyte reports financial results on a quarterly cadence, consistent with US-listed public companies. For the exact timing of upcoming earnings releases, check Veracyte's official investor relations page.
Is VCYT a good stock to buy?
UQS Score rates VCYT as Good overall. Its Risk pillar is Strong and Growth rates Good, while Quality and Moat are Neutral. Whether that profile suits your portfolio depends on your own investment criteria. The full pillar breakdown is available to UQS Pro members.
Is VCYT overvalued?
VCYT's Valuation pillar rates Good under the UQS framework, suggesting the market's current pricing is not considered excessive relative to the company's fundamentals. For the detailed valuation metrics behind that rating, sign up for a Pro account.
How does VCYT compare to its competitors?
Veracyte's closest listed peers include Zai Lab, Soleno Therapeutics, and Disc Medicine — each operating in different corners of healthcare. Veracyte is distinctive in its focus on multi-cancer genomic diagnostics and technology licensing, rather than drug development. Side-by-side UQS pillar comparisons are available on the platform.
What is VCYT's market cap bracket?
Veracyte is classified as a mid-cap company. This places it in a segment of the market that often balances growth potential with more established commercial operations than smaller peers, while remaining below the scale of large-cap diagnostics leaders.
Who founded Veracyte?
Veracyte was originally incorporated as Calderome, Inc. in 2006 before rebranding to Veracyte in March 2008. Founding details are widely available through public company filings and Veracyte's own corporate history resources.
Is VCYT a long-term quality indicator?
The UQS framework evaluates long-term quality through five pillars. VCYT's Strong Risk and Good Growth ratings suggest a business building toward durability, though Neutral Quality and Moat scores indicate the company is still developing the financial consistency and competitive advantages associated with the highest-rated long-term holdings.
What is the main competitive advantage of Veracyte?
Veracyte's edge lies in its proprietary genomic classifiers, which are backed by clinical evidence and integrated into physician workflows across multiple cancer types. Its technology licensing arrangements with partners like Johnson & Johnson add an additional layer of commercial reach. The Moat pillar currently rates Neutral, reflecting that this advantage is still maturing.
What sector does VCYT belong to?
Veracyte operates in the Healthcare sector, specifically within genomic diagnostics. It develops tests used in clinical settings to guide cancer diagnosis and treatment decisions, sitting at the intersection of molecular biology and precision medicine.
Unlock Full VCYT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for VCYT
- ✓Access full financial metrics and trend data
- ✓Compare VCYT against sector peers side by side
- ✓See the complete five-pillar breakdown in detail
- ✓Track UQS Score changes over reporting cycles
- ✓Explore curated screeners for diagnostics-sector stocks
Pro Analysis
VCYT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 59.6 | 49.5 | 41.0 | 79.5 | 82.4 | 58.0 | +2.5 |
| May 7, 2026 | 57.1 | 42.2 | 41.0 | 78.2 | 82.4 | 55.4 | -0.9 |
| May 3, 2026 | 58.0 | 42.2 | 41.0 | 78.2 | 82.4 | 61.1 | +0.2 |
| Apr 26, 2026 | 57.8 | 42.2 | 41.0 | 78.2 | 82.4 | 60.1 | -0.1 |
| Apr 19, 2026 | 57.9 | 42.2 | 41.0 | 78.1 | 82.4 | 60.6 | -0.1 |
| Apr 18, 2026 | 58.0 | 42.2 | 41.0 | 78.1 | 82.4 | 61.7 | -2.3 |
| Apr 14, 2026 | 60.3 | 42.2 | 41.0 | 78.1 | 82.4 | 77.1 | -0.2 |
| Apr 12, 2026 | 60.5 | 42.2 | 41.0 | 78.0 | 82.4 | 78.5 | +0.1 |
| Apr 6, 2026 | 60.4 | 42.2 | 41.0 | 78.0 | 82.4 | 77.3 | +4.1 |
| Apr 5, 2026 | 56.3 | 42.2 | 41.0 | 58.8 | 82.4 | 75.8 | -4.0 |
VCYT — Pillar Breakdown
Quality
— 48.0/100 (25%)Veracyte, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 79.5/100 (20%)Veracyte, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 82.4/100 (15%)Veracyte, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 53.9/100 (15%)Veracyte, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 41/100 (25%)Veracyte, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for VCYT.
Score Composition
Financial Data
More Stock Analysis
How is the VCYT UQS Score Calculated?
The UQS (Unified Quality Score) for Veracyte, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Veracyte, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Veracyte, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.